Drugs / KRC-01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07622017 | Jul 2026 → Jan 2029 expected | rectal cancer | Gustave Roussy, Cancer Campus, Grand Paris | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 10
| Date | Issuer | Release |
|---|---|---|
| 2024-10-12 | Kortuc, Inc. | Results A new article of KORTUC (KRC-01) was published in ”BJC Reports” kortuc.com ↗
This article demonstrates tumour reoxygenation by KORTUC in vitro/in vivo model, and shows its promising potential of KORTUC for the treatment of hypoxic tumors across various cancer types. |
| 2024-04-16 | Kortuc, Inc. | Results The Institute of Cancer Research (ICR) will present the preliminary results of clinical translational research in ongoing phase II study at ESTRO 2024. kortuc.com ↗
Preliminary results have shown interesting associations between radiation response and angiogenesis and immune / inflammatory pathways, including changes in tumor microvasculature following radiotherapy. |
| 2024-04-16 | Kortuc, Inc. | Results UZ Brussel group will present the result of KORTUC basic research at ESTRO2024. kortuc.com ↗
In this study, it was shown the new mechanism of action of KORTUC’s radiosensitizing effect involves the induction of ferroptosis in addition to apoptosis on tumor cells simultaneously under hypoxic conditions. |
| 2024-03-30 | Kortuc, Inc. | Regulatory Approval to initiate KRC-01 cervical cancer Phase I/II Study in the U.K. and Thailand kortuc.com ↗
We are pleased to announce that we have received approval from the MHRA (UK) and T-FDA (Thailand) to initiate a new phase I/II clinical trial for KRC-01 in cervical cancer. |
| 2023-05-29 | Kortuc, Inc. | Results KRC-01’s new basic research result will be presented at International Wolfsberg Meeting kortuc.com ↗
In this study, it was shown that the radiosensitizing effect of H2O2 under hypoxic conditions can be attributed to the inhibition of cellular respiration through a complex I (exist on the inner mitochondrial membrane) blockade, in addition to reoxygenating cells. |
| 2023-04-13 | Kortuc, Inc. | Results KRC-01’s new basic research result will be presented at ESTRO2023 kortuc.com ↗
In this study, it was shown that the radiosensitizing effect of H2O2 under hypoxic conditions can be attributed to the inhibition of cellular respiration through a complex I (exist on the inner mitochondrial membrane) blockade, in addition to reoxygenating cells. |
| 2023-03-15 | Kortuc, Inc. | Results Results from the Kortuc, Inc. and Okayama University research on KRC-01 tumor immunity will be presented at AACR 2023 kortuc.com ↗
This research demonstrates that KRC-01 — in combination with radiation and by tumor-specific immune activation — has an antitumor effect on untreated distant metastases lesions. |
| 2022-01-21 | Kortuc, Inc. | Results Results showing high efficacy and tolerable safety of Kortuc in several radioresistant cancer types were published in Molecular and Clinical Oncology. This shows KORTUC has potential to treat various types of cancer that are radioresistant kortuc.com ↗
Among the 186 patients who were followed-up, 15% showed a complete response (CR) and 32% a partial response. |
| 2021-09-24 | Kortuc, Inc. | Results Results showing high efficacy of Kortuc in treating locally advanced or recurrent breast cancer were published in Molecular and Clinical Oncology. These predict a positive outcome of the current pivotal Phase 2 study kortuc.com ↗
These results show that radiation therapy using Kortuc achieved a median maximum tumor shrinkage of 97%, and half of the patients were assessed to have achieved a clinical complete response. |
| 2020-06-21 | Kortuc, Inc. | Results KORTUC announces Red Journal publication of a Phase 1 study demonstrating a reliable safety profile and, as a secondary endpoint, an excellent tumor response which is likely to be confirmed in an ongoing pivotal Phase 2 study kortuc.com ↗
Among 12 patients with locally advanced breast cancer, no severe adverse event was identified, and other events were comparable to those for standard radiotherapy (RT) alone. |
All press releases naming this drug 35 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KRC-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07622017 ↗ |
| Known as | KORTUC | “KRC-01 (KORTUC)” NCT07622017 ↗ |
| Route | Other | “is injected directly into the tumor before radiotherapy sessions” NCT07622017 ↗ |